Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Silence Therapeutics plc's Zerlasiran has done well, but Eli Lilly's Muvalaplin is simply better. Read more about SLN stock ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

Chinese regulators approved the drug for the same subset of advanced, previously treated EGFR-mutated NSCLC patients in 2023.

• Performers: Ed Larkin, Jonny Amies, Linzi Hateley, Alasdair Harvey, Fran Fraser and Andrew Fraser, Jordan Benjamin, Rebecca Bowden, Jamie Chatterton, Gracie ...

A new drug application has been submitted to the FDA for dordaviprone to treat recurrent H3K27M-mutant diffuse glioma.

Note :Financial Information is based on consolidated numbers.